A Study of TQB3820 in Patients With Hematological Malignancies

Inclusion Criteria: 1. For Multiple Myeloma cohort 1. Patients must have received at least 2 prior therapies; 2. Measurable levels of myeloma paraprotein 1. M-protein in serum \>5 g/L; 2. M-protein in urine \>200mg/24h; 3. Light chain Multiple Myeloma without measurable disease in the serum or urine: serum immunoglobulin free light chain ≥ 100 mg/L and abnormal serum immunoglobulin kappa lambda free light chain ratio. 2. For Indolent B-NHL 1. Progressed after standard treatment or no standard treatment with an established survival benefit is available; 2. Imaging in screening showing at least one measurable lesion; In patients with CLL/SLL, circulating lymphocytes \>= 5.0 × 10\^9/L or lesions greater than 1.5 cm. 3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2; 4. Life expectancy \>=3 months; 5. Adequate organ/system function; 6. Female patients of childbearing age should agree to use contraceptive measures during the study period and for at least 6 months after study is stopped; male patients should agree to use contraception during the study period and for at least 6 months after study is stopped; Exclusion Criteria: 1. Patients received allogenic haemopoietic stem cell transplantation, or autologous stem cell transplantation within 3 months; 2. Diagnosed and/or treated additional malignancy within 3 years before the first dose; 3. With factors affecting oral medication; 4. Toxicity that is \>=Grade 2 caused by previous cancer therapy; 5. Patients with congenital bleeding or coagulopathy, or are being treated with anticoagulants; 6. Patients with uncontrolled infections; 7. Has received surgery, chemotherapy, radiotherapy or other anticancer therapies 2 weeks before the first dose; 8. Has received Chinese patent medicines with anti-tumor indications that National Medical Products Administration(NMPA) approved within 2 weeks before the first dose; 9. Pleural effusion, pericardial effusion or ascites that cannot be controlled and need repeated drainage; 10. Central nervous system metastases; 11. Has participated in other clinical studies within 4 weeks before the first dose; 12. According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.